SCHEMBL23225613

SCHEMBL23225613

CCCCN(C)C(=O)OCN1C(=O)c2c(ccn2COC(=O)N(C)CCCC)N(CCOC(C)C)C1S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23225722 0.70 OPRM1 (0.32) —
SCHEMBL29878679 0.61 EP300 (0.31) —
SCHEMBL29211250 0.61 — —
SCHEMBL23225606 0.59 OPRM1 (0.36) —
SCHEMBL29211252 0.57 OPRM1 (0.31) —
SCHEMBL25565603 0.56 ALDH1A1 (0.50) —
SCHEMBL11301771 0.56 CHRNB2 (0.40) —
SCHEMBL29879712 0.56 — —
SCHEMBL6273588 0.56 LMNA (0.41) —
SCHEMBL23225608 0.55 OPRM1 (0.40) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021072140-A1 PRODRUGS OF MYELOPEROXIDASE INHIBITORS BIOHAVEN THERAPEUTICS LTD. (US) 2021-04-15 — — WO disclosed
Send feedback